BAFNAPHARM

Bafna Pharmaceuticals Limited has informed the Exchange regarding outcome of Annual General Meeting held on September 10, 2014.

Bafna Pharmaceuticals Limited has submitted to the Exchange a copy of the minutes of proceedings relating announcement of Results of Postal Ballot (including voting by Electronic Means) by Company held on August 26, 2014.

Bafna Pharmaceuticals Limited has submitted to the Exchange a copy of the Results of Postal Ballot & the Scrutinizer's Report.

Bafna Pharmaceuticals Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company will remain closed from September 06, 2014 to September 10, 2014 (Both Days inclusive) for the purpose of Annual General Meeting to be held September 10, 2014.

Bafna Pharmaceuticals Limited has submitted to the Exchange a copy of advertisement of dispatch of Postal Ballot Notice.

Bafna Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 30-Jun-2014.

Bafna Pharmaceuticals Limited has submitted to the Exchange a copy of the Notice of Postal Ballot pursuant to Section 110 of the Companies Act, 2013 along with calendar of events for conducting Postal Ballot.

Bafna Pharmaceuticals Limited has informed the Exchange that at the Board Meeting held on July 21, 2014 the Board of Directors of the Company have decided for selling majority stake of branded generic business to Strides Arcolab Limited and in this connection entered into agreement(s) with Strides Arcolab Limited on July 21, 2014. Further, the Company has submitted a copy of press release dated July 21, 2014 titled "BAFNA PHARMACEUTICALS TO SELL MAJORITY STAKE OF BRANDED GENERICS BUSINESS TO STRIDES ARCOLAB".

Bafna Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its Board Meeting held on May 30, 2014, has not proposed dividend for FY ended March 31, 2014.

Bafna Pharmaceuticals Limited has informed the Exchange that the trading window for dealing with securities of the Company will be closed for the employees & Directors w.e.f. March 27, 2014 till the date of Board Meeting (both days inclusive) proposed to be held for consideration of audited financial results for the financial year ending March 31, 2014; and it will reopen after 24 hours of the publication of the aforesaid financial results.

Bafna Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 31-Dec-2013.

Bafna Pharmaceuticals Limited has informed the Exchange that the trading window for dealing with securities of the Company will be closed for the employees & Directors w.e.f. January 01, 2014 till the date of Board Meeting (both days inclusive) proposed to be held for consideration of unaudited financial results for quarter ending December 31, 2013; and it will reopen after 24 hours of the publication of the aforesaid financial results.

News Verification : The media had reports that " US based generic drug maker Mylan and two Indian Pharma Cos are in race to accquire Bafna Pharmaceuticals Ltd" . The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Bafna Pharmaceuticals Limited has vide its letter inter-alia stated, "We wish to clarify that the news report appearing in the section of media regarding Bafna Pharma are speculative. The Company has a policy of desisting to

Bafna Pharmaceuticals Limited has informed the Exchange, vide letter dated November 25, 2013 regarding the "Launch of new products Afenac, Nocaf, Izabof in domestic market".

Bafna Pharmaceuticals Limited has informed the Exchange vide letter dated November 20, 2013 regarding the" Launch of RARICAP injection in domestic market".

Bafna Pharmaceuticals Limited has submitted to the exchange the standalone financial results for the period ended 30-sep-2013.

Bafna Pharmaceuticals Limited has informed the Exchange regarding a Outcome of Annual General Meeting pursuant to Clause 35A of Listing Agreement.

Bafna Pharmaceuticals Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Company held on September 30, 2013.

Bafna Pharmaceuticals Limited has informed the Exchange that the proposed dividend, if approved at the ensuing Annual General Meeting will be distributed on or around October 5, 2013.

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 10, 2013 has transacted the following: (1) Appointment of Mr. Kamlesh Kumar as Additional Director (Non-Executive Independent Director). And further Mr. Kamlesh Kumar was made as a member of Audit Committee. (2) Cancelled 25,00,000 convertible Warrants allotted on January 13, 2012 for nonpayment of balance money within 18 months and forfeited the 25% (application) money paid at the time of allotment of warrants. (3) Proposed the appointment of Mr. Kamlesh Kumar, Inde

Bafna Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2013.

Bafna Pharmaceuticals Limited has informed the Exchange regarding "Address to investors - continued selling of our stock".

Bafna Pharmaceuticals Limited has informed the Exchange that the Company has received Merit Award for the year 2012 from the State Pharmaceuticals Corporation of Sri Lanka during the 16th SPC Suppliers Convention 2013.

Bafna Pharmaceuticals Limited has informed the Exchange that the Company's facility at Grantlyon has been approved by Ministry of Health and Social Welfare, Tanzania Food and Drugs Authority, The United Republic of Tanzania. With the help of this approval the Company can export to Tanzania.

Bafna Pharmaceuticals Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company will remain closed from September 21, 2013 to September 30, 2013 (Both Days inclusive) for the purpose of payment of dividend and Annual General Meeting of the Company to be held on September 30, 2013.

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 22, 2013, have: (1) Accepted the resignation of Mr. A. Sahasranaman, Independent Director with immediate effect, who has resigned due to personal commitments. Board placed on record their appreciation for the contribution made & valuable advices provided by him during him tenure. (2) Re-appointed Statutory Auditor subject to approval of shareholders in the forthcoming Annual General Meeting.

Bafna Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 22, 2013, titled "Bafna Pharmaceuticals Ltd. recommends 6% dividend for 2012-13".

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 20, 2013 has approved the re-appointment of Mr. Bafna Mahaveer Chand as Chairman & Managing Director and Mr. Paras Bafna as Whole Time Director.

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 20, 2013 has recommended a final dividend of Rs. 0.60 per equity share (6%), subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.

Bafna Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2013.

Bafna Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated May 10, 2013 titled "Bafna Pharmaceuticals double the sales of Raricap".

Bafna Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 03, 2013, titled" Bafna Pharmaceuticals receives product approval for Ghana".

Bafna Pharmaceuticals Limited has informed the Exchange vide letter dated May 02, 2013 that the Company has appointed M/s Minepro Communications for marketing serviecs. The Company had entered into agreement with M/s. Minepro Communications for marketing services which include advertising and publicity. The Company further confirms that : 1. The above Company for any of their associates have any shareholding in the Company. 2. None of the person from the above media companies appointed any nominee Director on the Board of the Company; or, 3. There is no management control or any potential c

Bafna Pharmaceuticals Limited has informed the Exchange that the Company has got assignment / registration of "RARICAP" Brand in favour of the Company in India. The same was earlier purchased from NR Jet Enterprises, an affiliate of JOHNSON & JOHNSON LIMITED during 2011. The brand "RARICAP" has a legacy of over 42 years in the market. It is promoted for iron deficiency anemia in pregnancy.

Bafna Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2012.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of the Board Meeting held on December 26, 2012.